Bharat Biotech's Covaxin gets approval for phase 2/3 trials on 2-18 year-olds
Highlights Bharat Biotech's Covaxin has got approval for phase 2/3 trials on 2-18 year-olds The trial will take place in 525 subjects at various sites, including AIIMS, Delhi, AIIMS, Patna and Meditrina Institute of Medical Sciences, Nagpur. New Delhi: The Hyderabad-based Bharat Biotech's COVID-19 vaccine Covaxin has got the necessary approval from an expert panel for conducting phase 2/3 trials on those aged between 2 to 18 years. According to news agency PTI, the drug maker’s anti-COVID vaccine was recommended by an expert panel (Subject Expert Committee) for phase II/III clinical trial ...